Purpose A subset of patients treated for Lyme disease report persistent or recurrent symptoms
of unknown etiology named post-treatment Lyme disease syndrome (PTLDS). This study …

Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease
in the United States with an estimated 476,000 cases per year. While historically, the long-…

It has long been observed in clinical practice that a subset of patients with Lyme disease
report a constellation of symptoms such as fatigue, cognitive difficulties, and musculoskeletal …

Background: The increased incidence and geographic expansion of Lyme disease has made
it the most common vector-borne infection in North America. Post-treatment Lyme disease …

Lyme disease is a tick-borne illness caused by the bacterium Borrelia burgdorferi , and
approximately 10 to 20% of patients report persistent symptoms lasting months to years despite …

Direct molecular tests in blood for early Lyme disease can be insensitive due to low amount
of circulating Borrelia burgdorferi DNA. To address this challenge, we have developed a …

Approximately 10% to 20% of patients optimally treated for early Lyme disease develop
persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease …

Persistent, subjective symptoms of unknown etiology following treatment for Lyme disease
have been termed post-treatment Lyme disease syndrome or chronic Lyme disease (PTLDS/…

The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to
overactive immunity including aberrant activity of the brain’s resident immune cells, microglia. …

Lyme disease can lead to neurological, cardiac, and rheumatologic complications when
untreated. Timely recognition of the erythema migrans rash of acute Lyme disease by patients …